PUBLISHER: IMARC | PRODUCT CODE: 1518571
PUBLISHER: IMARC | PRODUCT CODE: 1518571
The global early toxicity testing market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.2% during 2024-2032.
Early toxicity testing of new compounds is used to develop drugs and the extension of the therapeutic potential of existing molecules. It is carried out at pre-clinical stages on various biological systems to investigate the species, organs, and dose-specific toxic effects of a product. It can be performed in multiple ways, including in vivo on animals, in vitro in laboratories using assays, and in silico on a computer. It is also utilized for studying accidental exposures to a substance. Nowadays, the high-cost impact of late-stage failures of drug candidates is encouraging pharma companies to conduct early toxicity testing on investigational products.
Exposure to toxic chemicals occurs through skin contact, oral intake, or inhalation. Therefore, early toxicity testing has become a crucial process in various industrial applications for determining the degree of toxicity in products and ensuring that they are safe for human consumption and the environment. For example, it is extensively utilized in the food and beverage (F&B) industry to identify the adverse effects and characterize potential toxicants in products. Moreover, the rising prevalence of diseases and the requirement of novel drugs and biological products are encouraging the adoption of early toxicity testing to prevent the failure of candidate drugs at clinical trials. In addition, stringent regulations relating to public health welfare imposed by regulatory authorities are positively influencing the demand for early toxicity testing to determine the viability of drugs required for regulatory approval. Apart from this, the increasing usage of pesticides can pose risks to human health, which is promoting the use of early toxicity testing in the agriculture industry. Furthermore, the escalating demand for cosmetic products is expanding the application of early toxicity testing of cosmetic ingredients worldwide.
IMARC Group provides an analysis of the key trends in each sub-segment of the global early toxicity testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on technique and end user.
In Vivo
In Vitro
In Silico
Pharmaceuticals Industry
Food Industry
Chemicals Industry
Cosmetics Industry
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Charles River Laboratories International Inc., Danaher Corporation, Enzo Biochem Inc., Eurofins Scientific SE, Evotec A.G., Merck KGaA, PerkinElmer Inc., SGS S.A., Thermo Fisher Scientific Inc. and WuXi AppTec.